463 related articles for article (PubMed ID: 28606732)
21. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
22. The role of neoantigens in response to immune checkpoint blockade.
Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
[TBL] [Abstract][Full Text] [Related]
23. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
25. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
26. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
27. Targeting T Cell Co-receptors for Cancer Therapy.
Callahan MK; Postow MA; Wolchok JD
Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
[TBL] [Abstract][Full Text] [Related]
28. Immuno-regulatory antibodies for the treatment of cancer.
Honeychurch J; Cheadle EJ; Dovedi SJ; Illidge TM
Expert Opin Biol Ther; 2015 Jun; 15(6):787-801. PubMed ID: 25882106
[TBL] [Abstract][Full Text] [Related]
29. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Remon J; Besse B
Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
[TBL] [Abstract][Full Text] [Related]
31. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
32. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
33. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
Neubauer A
Internist (Berl); 2017 Apr; 58(4):409-423. PubMed ID: 28303311
[TBL] [Abstract][Full Text] [Related]
35. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
36. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
37. [Immune alterations in lung cancer - the new therapeutic approach].
Domagała-Kulawik J; Osińska I
Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
40. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
